News

Nona Biosciences Teams Up with Candid Therapeutics for T-Cel

Nona Biosciences Teams Up with Candid Therapeutics for T-Cel

Nona Biosciences and Candid Therapeutics Collaboration

Nona Biosciences, a leading global biotechnology company, recently announced a significant research collaboration and licensing agreement with Candid Therapeutics, a company renowned for its innovative approach in the development of next-generation T-cell engagers (TCEs). This partnership aims to explore T-cell engagers specifically designed for autoimmune diseases.

Financial Terms of the Agreement

The collaboration stipulates that Nona Biosciences could receive up to $320 million. This amount is inclusive of an initial upfront payment along with potential milestone payments based on the progress and success of the developed therapies. Importantly, Candid Therapeutics will take the lead on further product development after this initial agreement.

Advancing Therapeutic Innovations

Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed enthusiasm over the partnership, highlighting that the engagement represents a merging of advanced technology with innovative therapeutic strategies. Nona Biosciences employs its proprietary HBICE technology platform to create T-cell engagers that offer precision targeting and optimized safety and efficacy profiles, which are essential in addressing complex autoimmune disorders.

Key Technologies Used

With the utilization of the HBICE technology, Nona Biosciences is committed to supporting Candid Therapeutics in creating T-cell engagers with enhanced therapeutic potential. This collaboration is expected to pave the way for innovative treatments aimed at providing new hope to patients suffering from various autoimmune diseases.

About Nona Biosciences

Nona Biosciences specializes in delivering innovative technological solutions, guiding projects from the initial idea phase to investigational new drug (IND) application. Their vast array of services encompasses target validation, antibody discovery, and preclinical research. Through integrated antibody discovery services, Nona utilizes state-of-the-art methods that include single B cell screening and pharmacological evaluations.

Unique Capabilities

Among the distinguishing features of Nona Biosciences is the Harbour Mice technology, which produces fully human monoclonal antibodies. This technique supports various formats, including the traditional two light and two heavy chain variants, as well as the heavy chain only formats, facilitating the development of groundbreaking therapeutic products.

About Candid Therapeutics, Inc.

Candid Therapeutics, Inc. is at the forefront of clinical-stage biotechnology, primarily focusing on T-cell engagers aimed at B-cell depletion for the treatment of autoimmune diseases. Since its inception in 2024, the company has made significant strides with two lead antibody candidates that demonstrate promise in addressing multiple autoimmune disorders through targeted therapies.

Strategic Initiatives

With a vision to explore the full potential of T-cell engagers, Candid Therapeutics emphasizes the importance of utilizing a range of B-cell protein targets and varying depths of depletion. Their team, composed of experienced leaders in the biotechnology sector, brings a wealth of knowledge to advance their projects effectively.

Frequently Asked Questions

What is the purpose of the collaboration between Nona Biosciences and Candid Therapeutics?

The collaboration aims to develop next-generation T-cell engagers for the treatment of autoimmune diseases, leveraging both companies' technological capabilities.

What is the financial scope of the agreement?

Nona Biosciences stands to gain up to $320 million, which includes an upfront payment and potential milestone payments for the progress of the developed therapies.

What technologies does Nona Biosciences use?

Nona utilizes its proprietary HBICE technology platform, known for its precision targeting and flexible formats, to develop innovative T-cell engagers.

Who is leading the development efforts at Candid Therapeutics?

Candid Therapeutics is spearheaded by a team of executives with extensive experience in moving biotechnology programs through development.

What are the future plans for Candid Therapeutics?

Candid aims to advance its lead B-cell depleting TCE antibody drug candidates while exploring various autoimmune diseases through targeted therapeutic strategies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 12

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 27

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 46

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
SeoulTech's Liver Chip Makes Toxicity Testing Practical

Updated Category News Views 32

A Lab Tool Finally Built for the Messy Part Thousands of everyday chemicals are floating around commerce with thin toxicity records, and that is a lousy way to run a modern economy. Seoul National University of Science and Technology researchers have put forward a modular liver-on-a-chip platform aimed squarely at that gap: making environmental chemical testing more...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 111

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 93

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 116

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Starbucks Workers Unite in Major Strike Action Ahead of Holidays

Updated Category News Views 645

Starbucks Workers Prepare for Significant Strike Starbucks (NASDAQ: SBUX) workers, represented by a union encompassing more than 10,000 individuals, have announced plans for a strike in major cities like Los Angeles, Chicago, and Seattle. This strike is set to commence on Friday and is expected to last through the busy Christmas season. Union's Demands for Better...

Continue Reading
Discover Häagen-Dazs® Summer Blueberry Collection Now!

Updated Category News Views 140

Häagen-Dazs® Shops Launches Delicious Summer Blueberry Collection The summer season is here, and Häagen-Dazs® Shops embraces it with their enticing Summer Blueberry Collection. This delightful selection is all about providing a refreshing and revitalizing experience for ice cream lovers. With an exquisite range of flavors, including the brand's first-ever oat...

Continue Reading
Innovative Beef Supply Chain By Rancher's Sustainable Angus Alliance

Updated Category News Views 240

Transforming the Beef Supply Chain for Sustainability The Rancher's Sustainable Angus Alliance (RSAA) is actively engaging with beef retail partners who are committed to delivering top-notch Angus beef while emphasizing animal welfare and environmental responsibility. Founded by a group of visionary seedstock ranchers, RSAA aims to connect consumers with the rich heritage...

Continue Reading
Emerging Trends and Growth in Global Glucose Testing Market

Updated Category News Views 131

Overview of the Global Point-of-Care Glucose Testing Market The Point-of-Care Glucose Testing Market is experiencing significant growth, fueled by increasing rates of diabetes globally and a shift towards more accessible healthcare solutions. As patients and healthcare providers seek easier and more accurate ways to manage diabetes, this market is expected to thrive,...

Continue Reading
Artesian Resources Corporation Celebrates Strong Growth in 2025

Updated Category News Views 182

Artesian Resources Corporation's Impressive Performance Artesian Resources Corporation (NASDAQ: ARTNA), a distinguished provider of water and wastewater services on the Delmarva Peninsula, has recently disclosed its remarkable financial performance for the third quarter and year-to-date of 2025. The reports reveal significant increases in both revenue and net income,...

Continue Reading